Immunogenicity of GI-4000 vaccine in adjuvant consolidation therapy following definitive treatment in patients with stage I-III adenocarcinoma of the lung with G12C, G12D, or G12V KRAS mutations.
S. P. D'Angelo
No relevant relationships to disclose
B. J. Park
No relevant relationships to disclose
L. M. Krug
No relevant relationships to disclose
C. Crevar
No relevant relationships to disclose
C. E. Medina
No relevant relationships to disclose
D. K. Sumner
No relevant relationships to disclose
J. Richman
Employment or Leadership Position - GlobeImmune
Stock Ownership - GlobeImmune
C. Coeshott
Employment or Leadership Position - GlobeImmune
Stock Ownership - GlobeImmune
D. Apelian
Employment or Leadership Position - GlobeImmune
Stock Ownership - GlobeImmune
A. Cohn
Employment or Leadership Position - GlobeImmune
Stock Ownership - GlobeImmune
M. G. Kris
No relevant relationships to disclose
C. G. Azzoli
No relevant relationships to disclose